Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schönland SO. Hegenbart U, et al. Among authors: beimler j. Haematologica. 2017 Aug;102(8):1424-1431. doi: 10.3324/haematol.2016.163246. Epub 2017 May 18. Haematologica. 2017. PMID: 28522573 Free PMC article. Clinical Trial.
Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement.
Dietrich S, Schönland SO, Benner A, Bochtler T, Kristen AV, Beimler J, Hund E, Zorn M, Goldschmidt H, Ho AD, Hegenbart U. Dietrich S, et al. Among authors: beimler j. Blood. 2010 Jul 29;116(4):522-8. doi: 10.1182/blood-2009-11-253237. Epub 2010 Apr 7. Blood. 2010. PMID: 20375312 Free article.
[Systemic amyloidoses].
Schönland S, Blank N, Kristen AV, Beimler J, Ganten T, Hegenbart U. Schönland S, et al. Among authors: beimler j. Internist (Berl). 2012 Jan;53(1):51-64. doi: 10.1007/s00108-011-2952-y. Internist (Berl). 2012. PMID: 22033913 German.
Risk factors for AA amyloidosis in Germany.
Blank N, Hegenbart U, Lohse P, Beimler J, Röcken C, Ho AD, Lorenz HM, Schönland SO. Blank N, et al. Among authors: beimler j. Amyloid. 2015 Mar;22(1):1-7. doi: 10.3109/13506129.2014.980942. Epub 2014 Nov 7. Amyloid. 2015. PMID: 25376380
Obesity is a significant susceptibility factor for idiopathic AA amyloidosis.
Blank N, Hegenbart U, Dietrich S, Brune M, Beimler J, Röcken C, Müller-Tidow C, Lorenz HM, Schönland SO. Blank N, et al. Among authors: beimler j. Amyloid. 2018 Mar;25(1):37-45. doi: 10.1080/13506129.2018.1429391. Epub 2018 Jan 24. Amyloid. 2018. PMID: 29364741 Clinical Trial.
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Kimmich CR, Terzer T, Benner A, Dittrich T, Veelken K, Carpinteiro A, Hansen T, Goldschmidt H, Seckinger A, Hose D, Jauch A, Wörner S, Beimler J, Müller-Tidow C, Hegenbart U, Schönland SO. Kimmich CR, et al. Among authors: beimler j. Blood. 2020 Apr 30;135(18):1517-1530. doi: 10.1182/blood.2019003633. Blood. 2020. PMID: 32107537 Free article.
48 results